体外诊断酵素市场－全球产业规模、份额、趋势、机会及预测（依酵素类型、疾病类型、技术类型、最终用途、区域及竞争格局划分，2021-2031年）

全球体外诊断酵素市场预计将从 2025 年的 36.3 亿美元成长到 2031 年的 57.4 亿美元，复合年增长率为 7.94%。

这些酶，包括核酸酶和聚合酵素等特殊生物催化剂，对于促进检测生物检体中生物标记所需的特定生化反应至关重要。全球慢性病和感染疾病率的上升是推动市场扩张的根本原因，这导致对大量临床检测的需求持续成长。此外，人口老化加剧以及医疗保健产业对疾病早期检测的重视，也为这些关键试剂的消费量增加提供了强有力的支撑。

然而，该行业面临与严格法规环境相关的重大障碍，这会阻碍供应链效率和商业化进程。严格的合规要求往往会阻碍製造商推出新的诊断产品，导致原料采购延迟。据英国）称，到2024年，该行业82%的企业将受到监管不确定性的影响，导致创新产品进入市场的时间出现可量化的延迟。下游诊断领域的这些障碍直接限制了全球酵素市场的成长潜力。

市场驱动因素

次世代定序(NGS) 和分子诊断技术的创新正在改变酵素产业，对专用修饰试剂和高保真聚合酵素的需求日益增长。遗传疾病筛检和肿瘤学领域复杂基因组分析工作流程的采用，显着提高了定序通讯协定和样品製备中这些生物催化剂的使用量。这种对大规模试剂消耗的依赖，确保了供应商拥有持续的收入来源，而不仅仅依赖外汇的设备销售。例如，Qiagen NV 在 2024 年 2 月报告称，其非新冠相关产品系列在 2023 年按固定汇率计算增长了 8%，其中耗材（包括这些关键的酶试剂盒）占总净销售额的 85% 以上。

同时，即时检测（PoC）的普及正在将市场拓展到集中式实验室之外，从而推动了对适用于分散式环境的耐用、耐热酶的需求。快速、床边检测的趋势要求酵素无需低温运输基础设施即可保持灵敏度和稳定性，这促进了风干和冷冻干燥形式的酵素的发展。丹纳赫公司在2024年1月报告称，其子公司Sepeed在2023年第四季呼吸道检测收入约为6.5亿美元，这主要得益于快速分子检测的广泛应用，以此佐证了这一需求。为了支持如此大规模的检测网络，罗氏公司在2024年宣布，在前一年已在全球供应了290亿份诊断检测套组，凸显了全球诊断需求对酵素的巨大需求量。

市场挑战

严格的法律规范对全球体外诊断酵素市场的发展构成重大阻碍。由于生物催化剂是诊断试剂盒的关键组成部分，其市场成功与最终诊断设备的监管核准直接相关。当製造商面临严格的合规要求和漫长的核准流程时，新诊断工具的研发週期必然会延迟。这种监管摩擦扰乱了供应链，迫使酵素供应商调整生产以适应诊断试剂盒製造商难以预测的生产计划。结果，对这些关键原料的需求停滞不前，导致酵素生产商的收入下降。

这些瓶颈的影响正体现在企业降低对合规环境复杂的市场的重视程度。满足新标准所需的大量资源正在限制市场准入和创新。据欧洲医疗技术协会（MedTech Europe）称，由于新监管要求的复杂性，到2024年，主要体外诊断试剂製造商选择欧盟作为其主要上市区域的倾向下降了40%。新产品上市数量的显着下降与推动生物催化剂需求的诊断测试商业化程度降低直接相关，而这又与酵素使用量的减少密切相关。

市场趋势

将特异性酵素整合到液态生物检体工作流程中已成为一大趋势，推动了对能够高精度检测循环肿瘤DNA (ctDNA) 的灵敏生物催化剂的需求。与标准组织切片检查不同，这些非侵入性检测利用酵素（例如高活性聚合酵素和工程化连接酶）来有效分析低输入量生物样本中的分子残留病灶 (MRD)。这项发展需要不断开发能够增强讯号放大并降低复杂筛检程序中背景噪音的试剂。 Exact Sciences 在 2025 年 1 月强调了这一点，预测其 2024 年全年收入将达到 27.6 亿美元，并宣布推出其 MRD 检测产品 Oncodetect，凸显了特异性酶促工作流程在癌症诊断中的重要性。

同时，酵素在数位PCR (dPCR) 系统中的广泛应用正在催生一个专注于无需标准曲线即可进行绝对定量分析的细分市场。这项技术在病毒量检测和移植监测等重要临床领域正日益受到关注，这些领域都需要精确的拷贝数变异分析。 dPCR平台的快速发展催生了对耐热酶和可在奈米孔和微流体液滴中发挥作用的预混液的特定需求。 2025年2月，Bio-Rad Laboratories宣布对OncoCyte进行策略性投资，以将基于QX600液滴数位PCR系统的移植监测检测方法商业化。这正是酵素试剂在先进数位定量工具中日益普及的一个例子。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球体外诊断酵素市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依酵素类型（聚合酵素和转录酶、蛋白酶）
  • 依疾病类型（感染疾病、糖尿病、肿瘤、心臟病、肾臟病、自体免疫疾病、其他）
  • 依技术类型（组织学、分子诊断、临床化学）
  • 透过申请（製药/生物製药公司、学术/研究机构、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美体外诊断酵素市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲体外诊断酵素市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区体外诊断酵素市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲体外诊断酵素市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲体外诊断酵素市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球体外诊断酵素市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck KGaA
• Codexis, Inc.
• F. Hoffmann-La Roche Ltd.
• Amano Enzyme Inc.
• Advanced Enzymes Technologies Ltd.
• Biocatalysts Ltd.
• Amicogen Co., Ltd.
• Dyadic International Inc
• Baduhenna Topco Limited
• Thermo Fisher Scientific Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global In-vitro Diagnostics Enzymes Market is projected to expand from USD 3.63 Billion in 2025 to USD 5.74 Billion by 2031, registering a CAGR of 7.94%. These enzymes, which include specialized biocatalysts like nucleases and polymerases, are essential for facilitating the specific biochemical reactions required to detect biomarkers in biological specimens. This market expansion is fundamentally driven by the rising global incidence of chronic and infectious diseases, which creates a sustained demand for high-volume clinical testing. Additionally, the growing geriatric population and the healthcare sector's focus on early disease detection provide a strong foundation for the increasing consumption of these vital reagents.

Conversely, the industry confronts substantial hurdles related to strict regulatory environments that can hamper supply chain efficiency and commercialization efforts. Rigorous compliance requirements often establish obstacles for manufacturers introducing new diagnostic products, subsequently retarding the procurement of raw materials. According to the Association of British HealthTech Industries, 82% of the sector was affected by regulatory uncertainty in 2024, leading to quantifiable delays in market entry for innovations. These barriers within the downstream diagnostics sector directly limit the growth potential of the global enzymes market.

Market Driver

Innovations in Next-Generation Sequencing (NGS) and molecular diagnostics are transforming the enzyme industry by demanding specialized modification reagents and high-fidelity polymerases. As laboratories adopt intricate genomic workflows for genetic disorder screening and oncology, the use of these biocatalysts in sequencing protocols and library preparation has increased significantly. This dependence on high-volume reagent consumption secures a recurring revenue source for suppliers, separate from one-time equipment sales. For instance, Qiagen N.V. reported in February 2024 that its non-COVID portfolio expanded by 8% at constant exchange rates during 2023, with consumables-including these essential enzymatic kits-representing over 85% of total net sales.

Simultaneously, the proliferation of Point-of-Care (PoC) Diagnostic Testing is extending market reach beyond centralized labs, fueling the need for durable, thermostable enzymes suitable for decentralized environments. This trend toward rapid, near-patient testing necessitates enzymes that retain sensitivity and stability without cold-chain infrastructure, promoting advancements in air-dried and lyophilized formats. Illustrating this demand, Danaher Corporation reported in January 2024 that its subsidiary Cepheid achieved roughly $650 million in respiratory testing revenue in Q4 2023, driven by the strong adoption of rapid molecular assays. To sustain such vast testing networks, F. Hoffmann-La Roche Ltd noted in 2024 that it supplied 29 billion diagnostic tests globally the prior year, underscoring the massive quantity of enzymes needed for global diagnostics.

Market Challenge

Strict regulatory structures pose a significant obstacle to the advancement of the Global In-vitro Diagnostics Enzymes Market. Because biocatalysts are critical elements of diagnostic kits, their market success is tied directly to the regulatory clearance of the finished diagnostic devices. When manufacturers encounter rigorous compliance mandates and extended approval procedures, development schedules for new diagnostic tools are inevitably delayed. This regulatory friction interrupts the supply chain, forcing enzyme providers to align their production with the unpredictable schedules of diagnostic kit manufacturers, ultimately leading to stalled demand for these key raw materials and reduced revenue for enzyme producers.

The consequences of these bottlenecks are visible as companies deprioritize markets with complicated compliance landscapes. The heavy resource requirements needed to meet new standards have led to a contraction in market entry and innovation. According to MedTech Europe, the preference for the European Union as a primary launch region for major in-vitro diagnostic manufacturers fell by 40% in 2024 due to the complexity of emerging regulatory requirements. This marked decline in new product introductions correlates directly with reduced enzyme usage, as fewer diagnostic tests achieve commercialization to drive biocatalyst uptake.

Market Trends

The incorporation of specialized enzymes into liquid biopsy workflows is becoming a major trend, spurring demand for high-sensitivity biocatalysts that can detect circulating tumor DNA (ctDNA) with high precision. In contrast to standard tissue biopsies, these non-invasive tests utilize enzymes like hyper-active polymerases and engineered ligases to effectively analyze low-input biological samples for molecular residual disease (MRD). This evolution requires the ongoing creation of reagents that enhance signal amplification and reduce background noise in complex screening procedures. Exact Sciences Corp. highlighted this in January 2025, projecting full-year 2024 revenue of $2.76 billion and announcing the upcoming launch of Oncodetect, an MRD test that emphasizes the vital function of specialized enzymatic workflows in cancer diagnostics.

Concurrently, the increasing application of enzymes in Digital PCR (dPCR) systems is carving out a niche market dedicated to absolute quantification without relying on standard curves. This technology is gaining traction in critical clinical areas, such as viral load measurement and transplant monitoring, where accurate copy number variation analysis is required. The growth of dPCR platforms generates a specific need for thermostable enzymes and partitioning-compatible master mixes that function within nanowells or microfluidic droplets. In February 2025, Bio-Rad Laboratories, Inc. announced a strategic investment in Oncocyte to commercialize transplant monitoring assays using the QX600 Droplet Digital PCR system, illustrating the growing integration of enzymatic reagents in advanced digital quantification tools.

Key Market Players

• Merck KGaA
• Codexis, Inc.
• F. Hoffmann-La Roche Ltd.
• Amano Enzyme Inc.
• Advanced Enzymes Technologies Ltd.
• Biocatalysts Ltd.
• Amicogen Co., Ltd.
• Dyadic International Inc
• Baduhenna Topco Limited
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global In-vitro Diagnostics Enzymes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In-vitro Diagnostics Enzymes Market, By Enzyme Type

• Polymerase & Transcriptase
• Proteases

In-vitro Diagnostics Enzymes Market, By Disease Type

• Infectious disease
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune diseases
• Others

In-vitro Diagnostics Enzymes Market, By Technology Type

• Histology Assays
• Molecular Diagnostics
• Clinical Chemistry

In-vitro Diagnostics Enzymes Market, By End-Use

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

In-vitro Diagnostics Enzymes Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In-vitro Diagnostics Enzymes Market.

Available Customizations:

Global In-vitro Diagnostics Enzymes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In-vitro Diagnostics Enzymes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Enzyme Type (Polymerase & Transcriptase, Proteases)
  • 5.2.2. By Disease Type (Infectious disease, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, Others)
  • 5.2.3. By Technology Type (Histology Assays, Molecular Diagnostics, Clinical Chemistry)
  • 5.2.4. By End-Use (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America In-vitro Diagnostics Enzymes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Enzyme Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Technology Type
  • 6.2.4. By End-Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States In-vitro Diagnostics Enzymes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Enzyme Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Technology Type
      • 6.3.1.2.4. By End-Use
  • 6.3.2. Canada In-vitro Diagnostics Enzymes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Enzyme Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Technology Type
      • 6.3.2.2.4. By End-Use
  • 6.3.3. Mexico In-vitro Diagnostics Enzymes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Enzyme Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Technology Type
      • 6.3.3.2.4. By End-Use

7. Europe In-vitro Diagnostics Enzymes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Enzyme Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Technology Type
  • 7.2.4. By End-Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Enzyme Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Technology Type
      • 7.3.1.2.4. By End-Use
  • 7.3.2. France In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Enzyme Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Technology Type
      • 7.3.2.2.4. By End-Use
  • 7.3.3. United Kingdom In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Enzyme Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Technology Type
      • 7.3.3.2.4. By End-Use
  • 7.3.4. Italy In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Enzyme Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Technology Type
      • 7.3.4.2.4. By End-Use
  • 7.3.5. Spain In-vitro Diagnostics Enzymes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Enzyme Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Technology Type
      • 7.3.5.2.4. By End-Use

8. Asia Pacific In-vitro Diagnostics Enzymes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Enzyme Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Technology Type
  • 8.2.4. By End-Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Enzyme Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Technology Type
      • 8.3.1.2.4. By End-Use
  • 8.3.2. India In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Enzyme Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Technology Type
      • 8.3.2.2.4. By End-Use
  • 8.3.3. Japan In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Enzyme Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Technology Type
      • 8.3.3.2.4. By End-Use
  • 8.3.4. South Korea In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Enzyme Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Technology Type
      • 8.3.4.2.4. By End-Use
  • 8.3.5. Australia In-vitro Diagnostics Enzymes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Enzyme Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Technology Type
      • 8.3.5.2.4. By End-Use

9. Middle East & Africa In-vitro Diagnostics Enzymes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Enzyme Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Technology Type
  • 9.2.4. By End-Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia In-vitro Diagnostics Enzymes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Enzyme Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Technology Type
      • 9.3.1.2.4. By End-Use
  • 9.3.2. UAE In-vitro Diagnostics Enzymes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Enzyme Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Technology Type
      • 9.3.2.2.4. By End-Use
  • 9.3.3. South Africa In-vitro Diagnostics Enzymes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Enzyme Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Technology Type
      • 9.3.3.2.4. By End-Use

10. South America In-vitro Diagnostics Enzymes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Enzyme Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Technology Type
  • 10.2.4. By End-Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil In-vitro Diagnostics Enzymes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Enzyme Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Technology Type
      • 10.3.1.2.4. By End-Use
  • 10.3.2. Colombia In-vitro Diagnostics Enzymes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Enzyme Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Technology Type
      • 10.3.2.2.4. By End-Use
  • 10.3.3. Argentina In-vitro Diagnostics Enzymes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Enzyme Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Technology Type
      • 10.3.3.2.4. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global In-vitro Diagnostics Enzymes Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Codexis, Inc.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Amano Enzyme Inc.
• 15.5. Advanced Enzymes Technologies Ltd.
• 15.6. Biocatalysts Ltd.
• 15.7. Amicogen Co., Ltd.
• 15.8. Dyadic International Inc
• 15.9. Baduhenna Topco Limited
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer